Title: Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
Journal: Ophthalmology 20170101
Title: Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease.
Journal: Drugs of today (Barcelona, Spain : 1998) 20160901
Title: Lifitegrast: A novel drug for treatment of dry eye disease.
Journal: Journal of pharmacology & pharmacotherapeutics 20160101
Title: Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
Journal: Ophthalmology 20151201
Title: Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
Journal: Ophthalmology 20140201
Title: Integrin modulators: a patent review.
Journal: Expert opinion on therapeutic patents 20131001
Title: Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study.
Journal: Eye (London, England) 20120701
Title: Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.
Journal: ACS medicinal chemistry letters 20120308
Title: Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.
Journal: Biochimica et biophysica acta 20110801
Title: The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs.
Journal: Investigative ophthalmology & visual science 20110516
Title: Safety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 antagonist ophthalmic solution (SAR 1118) in healthy adults.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20110201
Title: Tear cytokine profiles in dysfunctional tear syndrome.
Journal: American journal of ophthalmology 20090201
Title: LFA-1 as a key regulator of immune function: approaches toward the development of LFA-1-based therapeutics.
Journal: Current pharmaceutical design 20060101
116700-73-3 | 2-Propen-1-ol, 2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]- | AA000CXQ | MFCD22571041